Will Vera Therapeutics stock go up?

According to Danelfin AI, Vera Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.95%) is +8.14% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Vera Therapeutics stock?

The Vera Therapeutics target price is $78.4 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Vera Therapeutics stock right now?

Vera Therapeutics has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (58.95%) is +8.14% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Vera Therapeutics stock is a good buy .

Is Vera Therapeutics undervalued right now?

Based on analysts, the average price target upside for Vera Therapeutics is +83.70% (1Y). According to Danelfin AI, Vera Therapeutics has today an AI Score of 7/10 (Buy Rating).

What was the price range of Vera Therapeutics stock over the past 12 months?

The Vera Therapeutics stock price range over the past 12 months has been $19.25 - $55.67.

What is going on with Vera Therapeutics stock in the last 3 months?

The Vera Therapeutics stock performance in the last quarter has been +6.09%.

Does Vera Therapeutics offer dividend payments?

No, Vera Therapeutics does not currently pay dividends.

What is the current market capitalization of Vera Therapeutics?

Vera Therapeutics's market cap is $3.06B, as of 2026-07-02 08:00.

When is the next VERA earnings report date?

VERA will publish its next earnings report on 2026-05-07.

Vera Therapeutics Inc (VERA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

VERA AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+4.05%
How the stock is priced relative to its fundamentals
Momentum+2.47%
Direction and strength of recent price movements
Sentiment+1.33%
How analysts and the market view the stock
Earnings Quality+0.35%
Stability and reliability of reported earnings
Size & Liquidity+0.29%
Company size and trading liquidity

Volatility-0.36%
How much the stock price tends to fluctuate
Growth-0.01%
Expected pace of revenue and earnings expansion

VERA probability advantage of beating the market (3M):

+8.14%

AI Score

Buy

Vera Therapeutics (VERA) has an AI Score of 7/10 (Buy) because, according to an overall analysis, it has a probability advantage of +8.14% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of VERA (58.95%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
VERA probability advantage of beating the market (3M)+8.14%
VERA probability of beating the market (3M)58.95%

VERA probability advantage of beating the market (3M): +8.14%

The AI-powered overall analysis of Vera Therapeutics (VERA) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of VERA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+3.39%
Sentiment	Industry (GICS)	Biotechnology	N/A	+1.55%
Technical	Chart Pattern (252d)	figure_13	N/A	+1.38%
Fundamental	Income (TTM)	-$368.95M	N/A	+1.00%
Fundamental	Operating Cash Flow (Qtr Discrete)	-106.5	N/A	+0.93%
Fundamental	Sloan Ratio	0.2		-0.76%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.74%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.74%
Fundamental	Cash per Share (MRQ)	8.31		+0.54%
Fundamental	Tangible Shareholders' Equity	499.7		+0.41%
Technical	Upgrade to unlock			-0.40%
Sentiment	Upgrade to unlock			-0.40%
Technical	Upgrade to unlock			+0.39%
Technical	Upgrade to unlock			-0.36%
Technical	Upgrade to unlock			-0.34%

Rest of Alpha Signals: +1.54%

VERA probability advantage of beating the market (3M)Total:+8.14%
VERA AI Score

Significant changes Vs previous day

VERA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$42.68
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

VERA Proven Buy Signal & Price Forecast

This is the price chart for VERA from January 1, 2026 until today. The chart indicates, in green, the 42 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

VERA Average Past Performance & Win Rate

Three months after its 98 Buy signals since July 2026, VERA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

98 Past VERA Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+53.60%
Average Alpha				+32.96%
Win Rate (% Positive Perf.)				25.00%
% Positive Alpha				25.00%

VERA Frequently Asked Questions

Will Vera Therapeutics stock go up?
According to Danelfin AI, Vera Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.95%) is +8.14% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Vera Therapeutics stock?
Is it a good time to buy, sell, or hold Vera Therapeutics stock right now?
Is Vera Therapeutics undervalued right now?
What was the price range of Vera Therapeutics stock over the past 12 months?
What is going on with Vera Therapeutics stock in the last 3 months?
Does Vera Therapeutics offer dividend payments?
What is the current market capitalization of Vera Therapeutics?
When is the next VERA earnings report date?

Vera Therapeutics Inc Company Profile

Engaged in the field of biotechnology, Vera Therapeutics Inc. concentrates on the discovery and development of treatments dedicated to patients suffering from grave immunological diseases. Their flagship product, atacicept – a fusion protein administered via subcutaneous injections – is presently in the third stage of clinical trials for treating patients with "IgA Nephropathy." In addition, it is currently under Phase II clinical testing for treating Lupus Nephritis.

Further developing its portfolio, Vera Therapeutics Inc. is also working on MAU868. This novel therapy is a human monoclonal antibody purposefully designed to treat BK viremia infections - revealing the company's unwavering commitment towards biomedical innovation.

Originally incorporated as Trucode Gene Repair, Inc., the company underwent a rechristening process and emerged as Vera Therapeutics, Inc. in April 2020. Established back in 2016, this innovative enterprise has managed to make its mark within a few years. Its corporate headquarters reside in Brisbane, California - a place where scientific thought merges with breakthrough technology.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:2000 Sierra Point Parkway, Suite 1200, Brisbane California
Employees:249
Website:veratx.com

Pros

Addressing unmet medical needs in immunological diseases

Potential for premium pricing for novel therapies

Market exclusivity potential from orphan drug designations

Acquisition attractiveness for larger pharmaceutical companies

High switching costs for patients on effective therapies

Cons

Substantial capital requirements for drug development

Binary outcomes inherent in clinical trial results

Extended timelines for drug development and commercialization

Regulatory approval uncertainty for investigational medicines

Competition from established pharmaceutical companies in immunology

Company	AI Score	Compare
VORVor Biopharma Inc
ATRAAtara Biotherapeutics Inc
BCABBioatla Inc
ZURAZura Bio Ltd
VYGRVoyager Therapeutics Inc

Company	AI Score	Compare
VORVor Biopharma Inc
ATRAAtara Biotherapeutics Inc
BCABBioatla Inc
ZURAZura Bio Ltd
VYGRVoyager Therapeutics Inc

VERA Stock AI Analysis